Physician profile
Dhan D Kaushal
NPI 1730186354
$11,842.69
in general payments reported to CMS, 2019-2025
49 companies · $4,049 in 2025
The $4,049 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $248 · 2021: $11.92 · 2022: $490 · 2023: $2,756 · 2024: $3,610 · 2025: $4,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,792 · Education: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,791.60 |
| Education | $623.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,055.45 | 2019-2025 | |
| Daiichi Sankyo INC. | $1,443.44 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Exelixis INC. | $850.81 | 2023-2025 | Cabometyx |
| Pfizer INC. | $750.43 | 2022-2025 | |
| Sobi, INC | $632.36 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $501.80 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Ipsen Biopharmaceuticals, INC | $448.00 | 2023-2025 | Onivyde, Somatuline Depot, Tazverik |
| Beigene USA, INC. | $391.11 | 2023-2025 | Brukinsa |
| Merck Sharp & Dohme LLC | $329.98 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genzyme Corporation | $251.81 | 2022-2024 | |
| Servier Pharmaceuticals LLC | $231.55 | 2023-2025 | Voranigo |
| Janssen Biotech, INC. | $228.32 | 2022-2025 | Talvey, Darzalex, Tecvayli |
| Regeneron Healthcare Solutions, INC. | $220.33 | 2023-2025 | Libtayo, Lynozyfic |
| Amgen INC. | $216.31 | 2022-2023 | Lumakras, Nplate, Xgeva |
| Celgene Corporation | $191.02 | 2022-2024 | Pomalyst, Reblozyl, Opdualag |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $181.66 | 2022-2025 | Tecentriq, Phesgo, Perjeta |
| Seagen INC. | $174.67 | 2023 | Adcetris, Padcev |
| Karyopharm Therapeutics INC. | $158.62 | 2022-2025 | Xpovio |
| Gilead Sciences, INC. | $157.18 | 2019-2025 | Trodelvy |
| Array Biopharma INC | $156.58 | 2023-2025 | Lorbrena, Braftovi, Mektovi |
| Sumitomo Pharma America, INC. | $155.85 | 2023-2025 | Orgovyx |
| E.R. Squibb & Sons, L.L.C. | $150.80 | 2020-2025 | Opdivo, Eliquis |
| Glaxosmithkline, LLC. | $147.54 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $138.57 | 2025 | |
| Astellas Pharma US INC | $134.04 | 2023-2024 | Xospata, Xtandi, Padcev |
| Beone Medicines USA, INC. | $133.88 | 2025 | Brukinsa, Tevimbra |
| Lilly USA, LLC | $133.13 | 2022-2025 | Verzenio, Jaypirca |
| Stemline Therapeutics INC. | $127.45 | 2023-2025 | Orserdu |
| Emd Serono, INC. | $127.22 | 2023-2025 | Bavencio, Tepmetko |
| Aveo Pharmaceuticals, INC. | $119.63 | 2024-2025 | |
| Geron Corporation | $108.40 | 2025 | Rytelo |
| Incyte Corporation | $107.83 | 2024-2025 | Jakafi, Monjuvi |
| Abbvie INC. | $101.63 | 2024-2025 | |
| Coherus Oncology, INC. | $65.22 | 2024-2025 | Loqtorzi |
| Genmab U.S., INC. | $63.86 | 2025 | Epkinly, Tivdak |
| Morphosys, US INC. | $57.14 | 2023 | Monjuvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.88 | 2023-2024 | Gilotrif |
| Sun Pharmaceutical Industries INC. | $54.89 | 2022-2024 | |
| Eisai INC. | $54.61 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.93 | 2024-2025 | Fruzaqla |
| Mirati Therapeutics, INC. | $39.56 | 2023 | Krazati |
| Myriad Women'S Health, INC. | $23.02 | 2023 | Precisetumor |
| Immunogen, INC. | $22.90 | 2023 | Elahere |
| Agios Pharmaceuticals, INC. | $22.14 | 2025 | Pyrukynd |
| Sirtex Medical INC | $18.49 | 2023 | Sir-Spheres Microspheres |
| Accord Healthcare, INC. | $17.12 | 2023 | |
| Forte Bio-Pharma LLC | $15.17 | 2023 | Prolate, Nalocet |
| Rigel Pharmaceuticals, INC. | $14.97 | 2023 | Tavalisse, Rezlidhia |
| Kite Pharma, INC. | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhan Kaushal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.